Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
|Title:||Amino acid formulations for patients with liver disease and method of using same|
|Abstract:||Amino acid formulations for administration to human patients with liver disease comprise mixtures of essential amino acids combined in novel relative proportions, and preferably also include non-essential amino acids. In particular, the combined molar proportions of isoleucine, leucine, and valine are from 40 to 300 times the molar proportion of tryptophan and from 15 to 135 times the molar proportion of phenylalanine, or phenylalanine and tyrosine. The formulations may be adapted for either intravenous or oral administration, but the preferred method of administration is by hyperalimentation infusion. The formulations and method can be utilized to provide nutritional support for liver diseased patients while reducing the incidence and severity of hepatic encephalopathy, and/or as primary therapy for treatment of hepatic encephalopathy.|
|Inventor(s):||Fischer; Josef E. (Boston, MA), Yoshimura; Norman N. (Woodland Hills, CA), Westman; Thomas L. (Northridge, CA), Deindoerfer; Fred H. (Northridge, CA)|
|Assignee:||Massachusetts General Hospital (Boston, MA) American Hospital Supply Corporation (Evanston, IL)|
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Dosage form; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.